Abstract
We study case-fatality risks (risks of dying in sick individuals) corresponding to the first wave of the COVID-19 pandemic in Mexico. Spatio-temporal analysis by state were performed, mainly from April to September 2020, including descriptive analyses through mapping and time series representations, and the fit of linear mixed models and time series clustering to analyze trends by state. The association of comorbidities and other variables with the risks were studied by fitting a spatial panel data linear model (splm). As results, we observed that on average the greatest risks were reached by July, and that highest risks were observed in some states, Baja California Norte, Chiapas, and Sonora; interestingly, some densely populated states, as Mexico City, had lower values. Different trends by state were observed, and a four-order polynomial, including fixed and random effects, was necessary to model them. The most general structure is one in which the risks increase and then decrease and was observed in states belonging to two clusters; however, there is a cluster corresponding to states with a retarded increase, and another in which increasing risks through time were observed. A cyclic behavior in terms of states having a second increasing trend was observed. Finally, according to the splm, percentage of men, being in the group of 50 years and over, chronic kidney disease failure, cardiovascular disease, asthma, and hypertension were positively associated with the case-fatality risks. This analysis may provide valuable insight into COVID-19 dynamics in future outbreaks, as well as the determinants of these trends at a state level; and, by combining spatial and temporal information, provide a better understanding of COVID-19 case-fatality.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external funding was received
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All the information in which this study is based on is freely available and does not require any ethics commitee aproval
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data available as supplementary material
